STOCK TITAN

NeoGenomics (NEO) EVP updates equity awards, reports tax-withholding share move

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

NeoGenomics EVP, GC & Business Development Alicia C. Olivo reported updated equity holdings in the company. The filing shows a disposition of 1,042 shares of common stock on May 1, 2026 as a tax-withholding transaction, leaving her with 92,182 common shares held directly.

Alongside these shares, she holds a range of equity awards in the form of restricted stock units, performance stock units and stock options tied to NeoGenomics common stock, with various exercise prices and expiration dates, reflecting a substantial, long-term incentive position rather than open-market trading activity.

Positive

  • None.

Negative

  • None.
Insider Olivo Alicia C
Role EVP, GC & Business Development
Type Security Shares Price Value
Tax Withholding Common Stock 1,042 $0.00 --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Performance Stock Unit -- -- --
holding Restricted Stock Unit -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Performance Stock Unit -- -- --
holding Restricted Stock Unit -- -- --
holding Restricted Stock Unit -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Restricted Stock Unit -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Restricted Stock Unit -- -- --
Holdings After Transaction: Common Stock — 92,182 shares (Direct, null); Stock Option (Right to Buy) — 1,046 shares (Direct, null); Performance Stock Unit — 19,508 shares (Direct, null); Restricted Stock Unit — 6,503 shares (Direct, null)
Footnotes (1)
  1. On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vest ratably over the first four anniversary dates of the grant date. On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date. On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date. On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date. On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date. On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date. On May 11, 2023, Ms. Olivo was granted 36,508 stock options. The options vest ratably over the first three anniversary dates of the grant date. On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company. Once vested, the shares of common stock are not subject to expiration. On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date. On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%. On February 21, 2025, Ms. Olivo was granted 107,450 stock options. The options vest ratably over the first three anniversary dates of the grant date. On February 21, 2025, Ms. Olivo was granted 63,238 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 27, 2026 and multiplied by 110%. On March 1, 2026, Ms. Olivo was granted 147,804 stock options. The options vest ratably over the first three anniversary dates of the grant date. On March 1, 2026, Ms. Olivo was granted 89,013 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
Tax-withholding shares 1,042 shares Common stock delivered for tax liability on May 1, 2026
Common shares held 92,182 shares Direct NeoGenomics common stock holdings after transactions
Stock options 2036 147,804 shares at $10.81 Options to buy common stock expiring March 1, 2036
Stock options 2035 107,450 shares at $13.05 Options to buy common stock expiring February 21, 2035
RSUs March 2026 grant 89,013 underlying shares Restricted stock units vesting over three years from March 1, 2026
RSUs February 2025 grant 63,238 underlying shares Restricted stock units vesting over three years from February 21, 2025
PSUs February 2024 grant 25,330 units (up to 37,996 shares) Performance stock units tied to share and revenue goals
Restricted Stock Unit financial
"On March 1, 2026, Ms. Olivo was granted 89,013 restricted stock units."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Performance Stock Unit financial
"On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance."
A performance stock unit is a type of reward companies give to employees, usually managers, that depends on how well the company performs over time. If the company hits specific goals, the employee earns shares of stock, like earning a prize for reaching certain levels in a game. It motivates employees to work hard because their rewards are tied to the company's success.
premium-price stock option financial
"This stock option was granted as a premium-price stock option."
tax-withholding disposition financial
"Payment of exercise price or tax liability by delivering securities"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
weighted average price financial
"based on the weighted average price of the Company's common stock over the 20-day trailing trading period"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Olivo Alicia C

(Last)(First)(Middle)
9490 NEOGENOMICS WAY

(Street)
FORT MYERS FLORIDA 33912

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
NEOGENOMICS INC [ NEO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, GC & Business Development
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/01/2026F1,042D$092,182D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$19.12 (1)09/30/2026Common Stock1,0461,046D
Stock Option (Right to Buy)$27.34 (2)05/01/2027Common Stock1,0241,024D
Stock Option (Right to Buy)$48.99 (3)05/01/2028Common Stock516516D
Stock Option (Right to Buy)$46.1 (4)08/01/2028Common Stock1,1171,117D
Stock Option (Right to Buy)$9.45 (5)05/01/2029Common Stock22,22222,222D
Stock Option (Right to Buy)$10.05 (6)09/01/2029Common Stock46,35546,355D
Stock Option (Right to Buy)$19.65 (7)05/11/2030Common Stock36,50836,508D
Performance Stock Unit$005/11/2026(8) (9)Common Stock19,50819,508D
Restricted Stock Unit$0 (10) (9)Common Stock6,5036,503D
Stock Option (Right to Buy)$16.45 (11)02/23/2034Common Stock42,34442,344D
Performance Stock Unit$002/23/2027(12) (9)Common Stock25,33025,330D
Restricted Stock Unit$0 (13) (9)Common Stock8,4438,443D
Restricted Stock Unit$001/13/2026 (9)Common Stock59,38259,382D
Stock Option (Right to Buy)$13.05(14) (15)02/21/2035Common Stock107,450107,450D
Restricted Stock Unit$0 (16) (9)Common Stock42,15942,159D
Stock Option (Right to Buy)$10.81(17) (18)03/01/2036Common Stock147,804147,804D
Restricted Stock Unit$0 (19) (9)Common Stock89,01389,013D
Explanation of Responses:
1. On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vest ratably over the first four anniversary dates of the grant date.
2. On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.
3. On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.
4. On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.
5. On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.
6. On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.
7. On May 11, 2023, Ms. Olivo was granted 36,508 stock options. The options vest ratably over the first three anniversary dates of the grant date.
8. On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.
9. Once vested, the shares of common stock are not subject to expiration.
10. On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
11. On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.
12. On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
13. On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
14. This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.
15. On February 21, 2025, Ms. Olivo was granted 107,450 stock options. The options vest ratably over the first three anniversary dates of the grant date.
16. On February 21, 2025, Ms. Olivo was granted 63,238 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
17. This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 27, 2026 and multiplied by 110%.
18. On March 1, 2026, Ms. Olivo was granted 147,804 stock options. The options vest ratably over the first three anniversary dates of the grant date.
19. On March 1, 2026, Ms. Olivo was granted 89,013 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
Remarks:
/s/ Alicia C. Olivo05/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider activity did NeoGenomics (NEO) report for Alicia C. Olivo?

NeoGenomics reported that EVP, GC & Business Development Alicia C. Olivo had 1,042 common shares withheld on May 1, 2026 to satisfy tax obligations. After this tax-related disposition, she directly held 92,182 NeoGenomics common shares plus multiple outstanding equity awards.

Was the NeoGenomics (NEO) Form 4 transaction a market sale of shares?

The Form 4 shows a tax-withholding disposition, not an open-market sale. 1,042 common shares were delivered to cover exercise price or tax liability, consistent with code F. This kind of transaction is mechanical and does not reflect a discretionary trade in the market.

How many NeoGenomics (NEO) common shares does Alicia C. Olivo hold after this filing?

After the May 1, 2026 tax-withholding disposition, Alicia C. Olivo directly holds 92,182 NeoGenomics common shares. This position is in addition to a significant portfolio of restricted stock units, performance stock units, and stock options linked to NeoGenomics stock.

What stock options does Alicia C. Olivo have according to this NeoGenomics (NEO) filing?

The filing lists several stock option grants, including 147,804 underlying shares at an exercise price of $10.81 expiring March 1, 2036, and 107,450 underlying shares at $13.05 expiring February 21, 2035. Additional smaller option grants have higher or lower exercise prices and nearer expirations.

What restricted stock units and performance stock units are reported for NeoGenomics (NEO) executive Alicia C. Olivo?

Olivo’s reported equity awards include 89,013 underlying common shares from restricted stock units granted March 1, 2026 and 63,238 from restricted stock units granted February 21, 2025. She also holds performance stock units, including 25,330 units granted February 23, 2024 tied to share-price and revenue goals.

How are NeoGenomics (NEO) performance stock units structured for Alicia C. Olivo?

Performance stock units granted to Olivo vest based on specific company goals. A 25,330-unit grant can vest up to 37,996 shares, with half tied to share growth based on weighted average price and half tied to cumulative fiscal-year revenue targets, all requiring continued service.